The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes and treatment patterns by tumor subtype (TS) in stage III inflammatory and non-inflammatory breast cancer (BC).
 
Jose Pablo Leone
Consulting or Advisory Role - Minerva Biotechnologies
Research Funding - Kazia Therapeutics (Inst); Lilly (Inst)
 
Julieta Leone
No Relationships to Disclose
 
Faina Nakhlis
No Relationships to Disclose
 
Ilana Schlam
No Relationships to Disclose
 
Kelly Hirko
No Relationships to Disclose
 
Aditi Hazra
No Relationships to Disclose
 
Jennifer Ruth Bellon
Honoraria - Grupo Oncoclinicas; MJH Life Sciences; uptodate; Varian Medical Systems
 
Carlos Teodoro Vallejo
No Relationships to Disclose
 
Nancy U. Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Artera; AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Johnson & Johnson/Janssen; Menarini; Olema Pharmaceuticals; Pfizer; Seagen
Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
Travel, Accommodations, Expenses - Olema Pharmaceuticals
 
Sara M. Tolaney
Consulting or Advisory Role - AADi; ARC Therapeutics; Artios Biopharmaceuticals; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; CytomX Therapeutics; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Infinity Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Menarini Group; Merck; Natera; Novartis; OncXerna Therapeutics; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Lilly; Sanofi
 
Filipa Lynce
Consulting or Advisory Role - AmerisourceBergen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Pfizer; Prime Education
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Bristol-Myers Squibb; CytomX Therapeutics (Inst); Immunomedics (Inst); Inivata (Inst)